GlassScriptPhysician profile
Belen Marie Ramirez
NPI 1275200727
$643.15
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $624 · 2024: $18.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $187.11 | 2023 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $77.72 | 2023 | Tezspire |
| Genentech USA, INC. | $69.60 | 2023 | Xolair |
| Genzyme Corporation | $42.96 | 2023 | |
| Pharming Healthcare, INC. | $36.52 | 2023 | Ruconest |
| Mylan Specialty L.P. | $34.05 | 2023 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $31.25 | 2023 | Dupixent |
| Novo Nordisk INC | $25.00 | 2023 | Rybelsus |
| Incyte Corporation | $19.84 | 2023 | Opzelura |
| Astrazeneca Pharmaceuticals LP | $19.80 | 2023 | Tezspire |
| Organon LLC | $18.93 | 2024 | |
| Blueprint Medicines Corporation | $18.20 | 2023 | Ayvakit |
| Abbvie INC. | $17.56 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.07 | 2023 | Cuvitru |
| Csl Behring | $14.58 | 2023 | Hizentra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $12.96 | 2023 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Belen Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.